Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer ® -Accredited Facilities in the United States

• Published in: Cancers 2024-03, Vol.16 (5), p.1071
• Main Authors: Sitler, Collin A, Tian, Chunqiao, Hamilton, Chad A, Richardson, Michael T, Chan, John K, Kapp, Daniel S, Leath, 3rd, Charles A, Casablanca, Yovanni, Washington, Christina, Chappell, Nicole P, Klopp, Ann H, Shriver, Craig D, Tarney, Christopher M, Bateman, Nicholas W, Conrads, Thomas P, Maxwell, George Larry, Phippen, Neil T, Darcy, Kathleen M
• Format: Article
• Language: English
• Subjects: Antibodies; Brachytherapy; Cancer; Cancer patients; Cancer therapies; Care and treatment; Cervical cancer; Cervical carcinoma; Chemotherapy; Clinical trials; Comorbidity; CT imaging; Death; Ethnicity; Immunotherapy; Medical diagnosis; Medical prognosis; Medical research; Medicine, Experimental; Metastases; Metastasis; Neighborhoods; Patient outcomes; Patients; Radiation therapy; Surgery; Survival; Trends; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16051071

To investigate IMT use and survival in real-world stage IVB cervical cancer patients outside randomized clinical trials. Patients diagnosed with stage IVB cervical cancer during 2013-2019 in the National Cancer Database and treated with chemotherapy (CT) ± external beam radiation (EBRT) ± intracavitary brachytherapy (ICBT) ± IMT were studied. The adjusted hazard ratio (AHR) and 95% confidence interval (CI) for risk of death were estimated in patients treated with vs. without IMT after applying propensity score analysis to balance the clinical covariates. There were 3164 evaluable patients, including 969 (31%) who were treated with IMT. The use of IMT increased from 11% in 2013 to 46% in 2019. Age, insurance, facility type, sites of distant metastasis, and type of first-line treatment were independently associated with using IMT. In propensity-score-balanced patients, the median survival was 18.6 vs. 13.1 months for with vs. without IMT ( < 0.001). The AHR was 0.72 (95% CI = 0.64-0.80) for adding IMT overall, 0.72 for IMT + CT, 0.66 for IMT + CT + EBRT, and 0.69 for IMT + CT + EBRT + ICBT. IMT-associated survival improvements were suggested in all subgroups by age, race/ethnicity, comorbidity score, facility type, tumor grade, tumor size, and site of metastasis. IMT was associated with a consistent survival benefit in real-world patients with stage IVB cervical cancer.